Immunotherapy Boost for Bile Duct Cancer Survival Holds Firm After Three Years
Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin chemotherapy maintains a durable ...
Tag: KEYNOTE-966
POPULAR NEWS
-
Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone
-
Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes
-
Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells
-
New Scale Measures How Ready Nurse Educators Really Are for the AI Era